Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Poteligeo (mogamulizumab-kpkc) is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Adult T-cell Leukemia-Lymphoma (ATL) Survival Outcomes: Mogamulizumab treatment demonstrated a median overall survival (OS) ranging from 2.2 to 17.6 months, with a 30% OS time ranging from 8.7 to 27.1 months. For comparison, allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed a median OS of 3.8 to 6.2 months and a 30% OS time of 7.5 to 19.8 months, while other chemotherapy treatments exhibited a median OS of 4.1 to 20.3 months and a 30% OS time of 7.1 to 17.0 months.
• Mycosis Fungoides (MF) Response Rates: The complete response (CR) rate to treatment in MF ranged from 0% to 83%, with a median CR of 31%. The objective response rate (ORR) varied between 0% and 88%, with a median ORR of 47%. Comparative studies of PUVA and its combinations with other treatments, such as intralesional IFN-α or bexarotene, indicated little to no difference in CR and ORR when combined with PUVA compared to PUVA alone.
• Mogamulizumab-associated cutaneous adverse events included rash (affecting up to 25% of patients), spongiotic/psoriasiform dermatitis (22%), papules and/or plaques (16.1%), cutaneous granulomatosis (11.4%), morbilliform or erythrodermic dermatitis (9.4%), and photodermatitis (7.1%); rash was the most frequent adverse event leading to drug discontinuation.
• Safety outcomes for mogamulizumab in Adult T-cell Leukemia-Lymphoma (ATL) were not detailed beyond general survival outcomes.
• There is no population types or subgroups information available in the reviewed studies.